Eleusis Therapeutics US Inc. has synthesized aryl-ring-substituted 3-phenylazetidines acting as 5-HT2 receptor ligands reported to be useful for the treatment of chronic pain, depression, atherosclerosis, chronic obstructive pulmonary disease, conjunctivitis, type 2 diabetes, multiple sclerosis and rheumatoid arthritis, among others.